Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts

• Published in: Biomedicine & pharmacotherapy 2023-08, Vol.164, p.114891-114891, Article 114891
• Main Authors: He, Tiantian, Du, Juan, Zhu, Keke, Zhou, Yixuan, Xiao, Zewei, Liu, Wenjie, Ren, Weiwei, Liu, Xiongying, Chen, Tongsheng, Liu, Wenjuan, Chen, Zhuanming, Ni, Guoying, Liu, Xiaosong, Wang, Tianfang, Quan, Jiangtao, Zhang, Peipei, Yuan, Jianwei
• Format: Article
• Language: English
• Subjects: Esophageal cancer; Iodine-131 labeling; Polypeptide c(RGD)2; Polypeptide caerin 1.1; TE-1 cells
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.114891

The aim of this study was to analyze and compare the therapeutic effects of 131I-caerin 1.1 and 131I-c(RGD)2 on TE-1 esophageal cancer cell xenografts. (1) The in vitro antitumor effects of the polypeptides caerin 1.1 and c(RGD)2 were verified by MTT and clonogenic assays. 131I-caerin 1.1 and 131I-c(RGD)2 were prepared by chloramine-T (Ch-T) direct labeling, and their basic properties were measured. The binding and elution of 131I-caerin 1.1, 131I-c(RGD)2, and Na131I (control group) in esophageal cancer TE-1 cells were studied through cell binding and elution assays. (2) The antiproliferative effect and cytotoxicity of 131I-caerin 1.1, 131I-c(RGD)2, Na131I, caerin 1.1 and c(RGD)2 on TE-1 cells were detected by Cell Counting Kit-8 (CCK-8) assay. (3) A nude mouse esophageal cancer (TE-1) xenograft model was established to study and compare the efficacy of 131I-caerin 1.1 and 131I-c(RGD)2 in internal radiation therapy for esophageal cancer. (1) Caerin 1.1 inhibited the in vitro proliferation of TE-1 cells in a concentration-dependent manner, with an IC50 of 13.00 µg/mL. The polypeptide c(RGD)2 had no evident inhibitory effect on the in vitro proliferation of TE-1 cells. Therefore, the antiproliferative effects of caerin 1.1 and c(RGD)2 on esophageal cancer cells were significantly different (P